Peer Exchange

Medical experts provide a comprehensive approach to proactively treathigh levels of LDL, highlighting lesser-known therapies and trials that could benefit the field and mitigatehyperchlolesteromia.

Hanford Yau, MD, Ralph DeFronzo, MD, Pam Kushner, MD, Honey East, MD, and Christopher Lucci, MD, discuss the challenges of managing patients with resistant diabetes, emphasizing key strategies for identifying and treatingunderlying hypercortisolismthat leads to resistant diabetes.

Experts extensively review the array of psoriasis treatments, from topicals to biologics, exploring the landscape of IL therapies and their enhanced safety and efficacy compared to previous agents. The physicians also highlight how common comorbidities may impact on treatment decisions.

Different clinical specialists in the management of inflammatory diseases discuss the role of adalimumab biosimilars in the treatment of their patients.

A panel of ophthalmologists and vitreoretinal specialists discuss treatments for retinal diseases, specifically neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Experts highlight two new therapies, aflibercept 8 mg and faricimab, and how the addition of biosimilars and gene therapy are changing the landscape of care for the better.

Leading dermatologists discuss management of psoriasis in patients with skin of color, including disease presentation, cultural stigma and its impact on patient’s quality of life. They also share recently presented and published data, highlighting use of biologics for treatment of psoriasis in patients with skin of color.

In an upcoming Peer Exchange program entitled “Dual-Orexin Receptor Antagonists for Treatment of Insomnia” Dr Paul Doghramji will moderate a conversation with physicians about this class of agents for treatment of insomnia and discuss other therapeutic advancements in the field.

Expert panelists discuss the need for early introduction of biologic therapy in Crohn’s disease, therapeutic targets in CD management, and advanced therapies for more effective CD treatment.

Expert cardiologists discuss the role of non-statin therapies in lowering LDL cholesterol, recent clinic trial data on who can benefit, as well as how to implement these agents into your clinical practice.

Expert dermatologists discuss the use of Janus kinase (JAK) inhibitors for the treatment of atopic dermatitis (AD). They review the nuances of currently approved JAK inhibitors, share treatment considerations for AD, and discuss utilizing JAK inhibitors in clinical practice.

A straight forward approach to taking care of patients with Hepatitis C. Experts in the field are offering a simplified overview for new providers on the who, what, where and when of hepatitis C care, as well as practical tips for treatment implementation

Dermatologists discuss the burdens, unmet needs, and emerging treatment options for patients with seborrheic dermatitis, offering clinical insights on therapeutic approaches and the importance of patient-centered care.

Expert cardiologists discuss strategies to improve control of LDL-cholesterol in high-risk individuals as well as real world data on reaching LDL-cholesterol thresholds. They will cover emerging therapies for lipid lowering and strategies to help implement lipid lowering therapies into your clinical practice.

Expert endocrinologists explore the pathophysiology of type 1 diabetes (T1D) and delve into screening and staging processes. They discuss strategies for delaying its onset and provide insight into the future of T1D management.

In an upcoming Peer Exchange experts in cardiology will discuss novel treatment approaches for obstructive hypertrophic cardiomyopathy.

Expert dermatologists discuss factors guiding treatment selection in plaque psoriasis and the role of emerging novel topical agents.

An expert panel discusses new evidence to guide personalized care in heart failure. They focus on updates in the most recent heart failure guidelines, review guideline-directed medical therapy, and discuss the new clinical trial data in specific patient populations.

Experts in hepatology discuss recent updates in primary biliary cholangitis (PBC) treatment and monitoring. They review recently published real-world data and share their approach to personalizing treatment and what is on the horizon for PBC care.

A panel of experts discuss the role of type 2 inflammation in asthma, challenges with long-term use of corticosteroids, and the emerging role of biologics and various mechanisms of actions in the management of asthma.

Experts discuss therapies and sequencing strategies for treating inflammatory bowel disease, highlight the efficacy and safety of these treatments, and explore prospective advances in the care of patience with inflammatory bowel disease.

Experts discuss gut microbiota, current and emerging microbiome-based therapies for C difficile, and the practical ways to incorporate these treatments into your clinical practice.

A panel of medical experts discuss the current treatment landscape surrounding atopic dermatitis.

Experts in dermatology focus on how new and advanced treatments are impacting the quality of life for individuals with atopic dermatitis (AD). They explore how to optimize the patient experience by utilizing these therapies in a strategic matter.

Experts in dermatology discuss the pathophysiology of vitiligo, current standards of care, and new and emerging therapies. They also explore evidence-based approaches and patient-centered care to manage vitiligo and improve patient outcomes.

In this upcoming program, experts discuss the importance of correct diagnosis and early treatment of rare dermatologic disorders and best practices for critical care physicians in managing these conditions.

Experts discuss several topics pertaining to dry eye disease, including challenges and unmet needs, current and emerging treatment options, and tailoring treatment strategies based on individual patient factors.

Expert retina specialists discuss long-term experience with anti-VEGF therapies for age-related macular degeneration and diabetic macular edema, and share evidence-based strategies to improve treatment outcomes.

Updates in the management of immune-mediated kidney diseases; challenges in diagnosis of immunoglobulin A nephropathy (IgAN) and C3 glomerulopathy (C3G), current management and emerging treatment options.

In this program, our expert panel discusses several topics pertaining to type 1 diabetes, including screening and diagnosis, current and emerging treatments, and the role of clinicians in early testing and patient education.